Exclusive Summary

• Zero patent barriers for rapid entry: With patents completely expired, distributors can quickly launch and commercialize the product without intellectual property risks.
• Ultimate cost leadership: Leveraging China's mature API supply chain, the per-tablet cost is ultra-low, perfectly matching the demands of Low- and Middle-Income Countries (LMICs) and price-sensitive markets.
• Deep-rooted patient habits in specific regions: In specific emerging markets like the CIS, Africa, and parts of Southeast Asia, this compound maintains a massive legacy patient base due to its rapid onset and strong synergistic pain relief.
• Filling the niche supply gap: As multinational pharma companies have ceased production of this classic formulation, Chinese GMP-compliant suppliers can securely fill the rigid supply gap in regional markets, ensuring stable distribution and high margins.